Martin Shkreli

Allegedly acting on a complaint from Martin Shkreli, the Federal Trade Commission is about to file charges against Mallinckrodt PLC (NYSE: MNK), which maintains a monopoly on lupus and multiple sclerosis treatment and has hiked prices 2,165 percent over the years. The suit is expected to...

Pharmaceutical compounder Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) first stepped onto the national stage in December 2015, when the company announced its partnership with Express Scripts Holding Company (NASDAQ: ESRX) to distribute a $1 Daraprim alternative following Martin Shkreli and Turing...

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), which saw a move above the $130 handle in the aftermath of its financial results released on October 27, have lost some of the sheen now. Alexion's third-quarter results showed that the company reversed to a profit of $0.42 per share...

Shares of Mast Therapeutics Inc (NYSE: MSTX) fell 83 percent in Tuesday’s after-hours session after the company announced its phase-3 EPIC trial of vepoloxamer for the treatment of sickle cell disease patients experiencing vaso-occlusive crisis failed to meet its primary efficacy...

Martin Shkreli joined Benzinga's PreMarket Prep on Monday morning, so of course we were going to ask him his thoughts on the Mylan NV (NASDAQ: MYL)-EpiPen controversy. "From a fairness perspective, it's not very fair,” the provocative biotech exec told Benzinga. The co-...

Martin Shkreli thinks Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) is wildly undervalued. Shkreli, who appeared on Monday's edition of PreMarket Prep, said even though the the biotech's stock has "been pummeled" in recent months, "if you run the numbers, it...

Shares of Raptor Pharmaceutical Corp. (NASDAQ: RPTP) were trading higher by more than 20 percent Monday after the company agreed to be acquired by Horizon Pharma PLC (NASDAQ: HZNP) for $800 million, or $9 per share. Speaking as a guest on Monday's Premarket Prep, Martin Shkreli shared his...

Make sure you have a pot of coffee ready. Martin Shkreli will join PreMarket Prep for an exclusive interview on Monday at 8:15 a.m. ET. Last week, Retrophin Inc (NASDAQ: RTRX) announced positive results from sparsentan, a mid-stage clinical trial in patients suffering from a rare kidney...

After his former company Retrophin Inc (NASDAQ: RTRX) released positive top-line data from the Phase 2 DUET study of sparsentan, Martin Shkreli offered an olive branch to media companies wishing to speak to him on the drug he helped develop. With that, Benzinga reached out to Shkreli and...

Martin Shkreli, co-founder of the hedge fund MSMB Capital Management, co-founder and former CEO of the biotechnology firm Retrophin Inc (NASDAQ: RTRX), and founder and former CEO of Turing Pharmaceuticals, was back in court on Monday. Shkreli -– dubbed by the media as “the most...

Benzinga recently had the chance to speak with Imprimis Pharmaceuticals Inc (NASDAQ: IMMY)’s Founder and CEO, Mark L. Baum J.D., one of the few guys in the pharma industry who’s doing something to fight drug price-gouging. A Little Background Imprimis develops, produces and...

Looking for another reason to dislike drug companies? Good news: Some companies systematically use charitable giving as a way to raise their drug prices with minimal public awareness. Bloomberg’s Benjamin Elgin and Robert Langreth reported on a number of cases in which drug companies seem...

There’s plenty of things happening in global markets these days for investors to be bothered about. Benzinga recently took to Twitter to ask investors about four headlines to see which one is bothering them the most: 1.) A celebrity Republican presidential frontrunner with no political...